Replies to post #19373 on NSS ~ Counterfeiting Stock ~ MM Games Played

[fourkids_9pets]

CTIX .. loving the foundation being laid for Cellceutix

Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, is pleased to announce today the addition of another senior executive to its management team. Jane Harness, MS, MP, has been appointed to the role of Vice President, Clinical Sciences and Portfolio Management.

This new hire comes two months after pharmaceutical executive, Arthur P. Bertolino, MD, PhD, MBA, joined Cellceutix as President and Chief Medical Officer.

Ms. Harness is a seasoned industry executive with over 20 years of experience in clinical drug development, which will significantly broaden Cellceutix's management capabilities going forward.

Ms. Harness will direct all management aspects toward advancing the Company's pipeline, with a particular focus on clinical trials. Ms. Harness has successfully led numerous teams in executing clinical studies both internationally and domestically. Her expertise spans early and late-phase therapeutic programs at both large pharma, such as Pfizer and Novartis, and at smaller specialty companies. She possesses extensive experience in the areas of Dermatology, as well as Inflammation and Immunology. Ms. Harness has also run clinical trials in other therapeutic areas and has provided key leadership in project management and strategy.

4kids

[fourkids_9pets]

Cellceutix Corporation to Present at Upcoming Conferences

BEVERLY, MA--(Marketwired - September 07, 2016) - Cellceutix Corporation (OTC: CTIX) ("the Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces that management will present at two upcoming conferences highlighting the continuing advancement of the Company's clinical programs.


Friday, September 9, 2016 - Cellceutix will present at the 23rd Annual Newsmakers in the Biotech Industry Conference in New York City at 8:30 am ET. This presentation will be made available in the Investors section of the cellceutix.com website.
Monday, September 19, 2016 - Cellceutix will present, and participate in multiple panel discussions, at the 14th Annual Discovery on Target Conference in Boston. The Company's main presentation is titled, "Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis", and will be made available in the Investors section of the cellceutix.com website.


Alerts:

Sign-up for Cellceutix email alerts is available at
http://cellceutix.com/email-alerts/ - sthash.CRfqSmmY.k6MzKBo8.dpbs

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its plans for a Phase 2 study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol completed a Phase 2 trial and Cellceutix is now setting up a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.


Copyright © 2016 Cellceutix Corporation, All rights reserved.
You requested to receive email alerts about Cellceutix at our website www.cellceutix.com
Our mailing address is:
Cellceutix Corporation
100 Cummings Center, Suite 151-B
Beverly, MA 01915